Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Ependymoma/Ependymal tumors
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 40 for your search:
Start Over
Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: OSU-12161, NCI-2014-01110, NCT02193568
Fluorescence-guided Surgery for Low- and High-grade Gliomas
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB#10BN132, NCT01502280
Radiosurgery for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: 2006P-000464, NCT00456612
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 10C03, STU00040150, NCT01325207
Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11090804, VABC; GCR, NCT01721577
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: NLG2102, NCT02052648
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AG221-C-003, NCT02273739
Treating Patients With High-Grade Glioma With Intra-Arterial (IA) Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-922, ONC-02059-L, 922, 7328, OHSU-7328, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6803, NCI-2010-00714, P30CA015704, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 104974, NCT00961090
Antineoplaston Therapy in Treating Patients With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000066489, BC-BT-9, NCT00003457
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000066512, BC-BT-21, NCT00003475
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: Poly ICLC, 004385, NCT01188096
Carboplatin and Bevacizumab for Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CERN09-02, NCI-2011-01283, NCT01295944
Proton Radiation Therapy for Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10-439, NCT01358058
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: IRB00051663, WCI1999-11, NCT01445691
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 11C02, STU00053636, NCI CTRP#, NCT01478321
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-002165, NCT02104310
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: RERTEP, NCI-2014-00906, NCT02125786
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
A Phase I Dose Escalation Study for Patients With Recurrent Malignant Gliomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRUSZACT0073 (06-0870), NCT00721292
Dexanabinol in Patients With Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111827, NCT01654497
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI57337, NCT01672463
Start Over